Corbus Pharmaceuticals股价在盘前交易中上涨4.8%,此前美国食品药品监督管理局(FDA)授予该公司针对头颈部癌症的抗体药物联合疗法快速通道地位。
Corbus Pharmaceuticals股价在盘前交易中上涨4.8%,此前美国食品药品监督管理局(FDA)授予该公司针对头颈部癌症的抗体药物联合疗法快速通道地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.